AU2016204324A1 - Antibody formulation - Google Patents

Antibody formulation

Info

Publication number
AU2016204324A1
AU2016204324A1 AU2016204324A AU2016204324A AU2016204324A1 AU 2016204324 A1 AU2016204324 A1 AU 2016204324A1 AU 2016204324 A AU2016204324 A AU 2016204324A AU 2016204324 A AU2016204324 A AU 2016204324A AU 2016204324 A1 AU2016204324 A1 AU 2016204324A1
Authority
AU
Australia
Prior art keywords
formulation
antibody formulation
methods
antibody
ghmatters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016204324A
Inventor
Mary Cromwell
Yatin R. Gokarn
Timothy J. Kamerzell
Megan Li
Hong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013202276A external-priority patent/AU2013202276B2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU2016204324A priority Critical patent/AU2016204324A1/en
Publication of AU2016204324A1 publication Critical patent/AU2016204324A1/en
Priority to AU2017279638A priority patent/AU2017279638A1/en
Abandoned legal-status Critical Current

Links

Abstract

The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior 5 lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation. 7899286_1 (GHMatters) P90324.AU.2
AU2016204324A 2009-12-21 2016-06-24 Antibody formulation Abandoned AU2016204324A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016204324A AU2016204324A1 (en) 2009-12-21 2016-06-24 Antibody formulation
AU2017279638A AU2017279638A1 (en) 2009-12-21 2017-12-20 Antibody formulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61/288,535 2009-12-21
AU2013202276A AU2013202276B2 (en) 2009-12-21 2013-04-02 Antibody formulation
AU2016204324A AU2016204324A1 (en) 2009-12-21 2016-06-24 Antibody formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2013202276A Division AU2013202276B2 (en) 2009-12-21 2013-04-02 Antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017279638A Division AU2017279638A1 (en) 2009-12-21 2017-12-20 Antibody formulation

Publications (1)

Publication Number Publication Date
AU2016204324A1 true AU2016204324A1 (en) 2016-07-14

Family

ID=56682824

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016204324A Abandoned AU2016204324A1 (en) 2009-12-21 2016-06-24 Antibody formulation
AU2017279638A Abandoned AU2017279638A1 (en) 2009-12-21 2017-12-20 Antibody formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017279638A Abandoned AU2017279638A1 (en) 2009-12-21 2017-12-20 Antibody formulation

Country Status (1)

Country Link
AU (2) AU2016204324A1 (en)

Also Published As

Publication number Publication date
AU2017279638A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
MY159156A (en) Antibody formulation
AR124140A2 (en) ANTIBODY FORMULATIONS
MX2009006594A (en) Formulations.
MX2012007684A (en) Ligand-directed covalent modification of protein.
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
EP4233892A3 (en) Stable anti-ifnar1 formulation
AR097791A1 (en) ANTI-PDL1 ANTIBODY FORMULATIONS
NZ708103A (en) Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
MX2019006633A (en) Antibody formulations.
TN2009000382A1 (en) Stable antibody formulations
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
TN2012000023A1 (en) Subcutaneous anti-her2 antibody formulation
WO2007095337A3 (en) Antibody formulation
MX2010008035A (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof.
PE20181790A1 (en) METHODS TO TREAT OR PREVENT CHOLESTEROL-RELATED DISORDERS
NZ599176A (en) Immunoconjugate formulations
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
PH12019501796A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
WO2012003470A3 (en) Antibody formulations
EP4219560A3 (en) Integrin alpha v beta 8 neutralizing antibody
MX2017003121A (en) Antibody formulations.
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use
MX2007010930A (en) Formulation for aviptadil.
WO2013006766A3 (en) Formulations that stabilize proteins
AU2016204324A1 (en) Antibody formulation

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted